Search Results
Your search for ,kEY matches 7151 pages
Showing 1501 - 1550Preferred Sites of Cancer Care: Community Oncology Practices vs Hospitals and Academic Centers
Investigators uncovered that community oncology practices emerged as the preferred sites of service for cancer treatment compared with hospitals and academic centers, according to a recent case study. The findings may challenge the common perception of hospitals and academic centers as preferable...
Risk of Arterial Thromboembolism in Japanese Patients With Cancer
In a Japanese retrospective study reported in JACC:CardioOncology, Gon et al identified the incidence and outcomes of arterial thromboembolism in patients with cancer. Study Details The study used data on 97,448 patients with cancer (median age = 70 years) from the Osaka Cancer Registry linked with ...
Metastatic Urothelial Cancer: NECTIN4 Amplification and Response to Enfortumab Vedotin
In a study reported in the Journal of Clinical Oncology, Klümper et al established a fluorescence in situ hybridization (FISH) assay to measure NECTIN4 copy number variations and found that NECTIN4 amplification was associated with high activity of the anti-NECTIN4 antibody-drug conjugate...
Salvage Reirradiation for Locally Recurrent Prostate Cancer: 7-Year Follow-up
In an update of a Norwegian trial reported in the Journal of Clinical Oncology, Ekanger et al found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good outcomes. Study Details The study included 38 patients with locally recurrent disease ...
Pediatric AML: Comparison of Induction Regimens
In the phase III AML2012 trial, which had early termination of enrollment and results of which were reported in the Journal of Clinical Oncology, Tierens et al found that mitoxantrone-based induction resulted in better outcomes vs liposomal daunorubicin–based induction in pediatric patients with...
Older Patients With Newly Diagnosed Hodgkin Lymphoma: Preexisting Heart Failure and Survival Outcomes
In a study reported in JACC: CardioOncology, Upshaw et al found that preexisting heart failure was associated with an increased risk of lymphoma and cardiovascular mortality among patients aged ≥ 65 years who were newly diagnosed with Hodgkin lymphoma. The study used linked Surveillance,...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 and continuing through age 74 (B grade recommendation). More ...
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy alone in patients with early-stage non–small cell...
MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...
Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
In a French noncomparative phase II trial (PRODIGE 59-FFCD 1707-DURIGAST) reported in JAMA Oncology, Tougeron et al found limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-line treatment of advanced...
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal...
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting
In a study reported in JACC:CardioOncology, Rankin et al analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment for cancer reported cardiovascular eligibility criteria and adverse events. As stated by the...
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
In a study reported in a research letter in JAMA Oncology, Storgard et al identified the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Study Details The study used...
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
The current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients, according to a recent systematic review published by Gilmore et al in the Journal of the American Geriatrics Society. The findings revealed an urgent need...
AI Analysis of Cell-Free DNA Fragments and Protein Biomarkers for Noninvasive Detection of Ovarian Cancer
A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high specificity of more than 99%, according to study results by Medina et al.1 It noninvasively recognized ...
Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer
In a UK-based prospective cohort study reported in The Lancet Oncology, Turtle et al found that among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those without a cancer diagnosis. Study Details The study included...
Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment with vismodegib and curative-intent radiation therapy showed efficacy in patients with locally advanced unresectable basal cell carcinoma. ...
Functional Disability Among U.S. Cancer Survivors, 2017–2022
In a study reported in the Journal of Clinical Oncology, Cao et al found that U.S. adult cancer survivors had higher levels of mobility disability and self-care disability than adults without a cancer diagnosis. Study Details The study focused on data from 47,768 adult cancer survivors (aged ≥ 18...
Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors
In a study reported in JAMA Oncology, Kristen D. Brantley, PhD, MPH, and colleagues identified the risk of a second primary breast cancer among survivors of breast cancer diagnosed at age 40 or younger, including among women with and without germline pathogenic variants. Study Details The study...
A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and enrich global oncology. I recently had the privilege to speak with Ouissam Al Jarroudi, MD, about her...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...
Oxaliplatin-Based Adjuvant Therapy in Older Patients With Stage III Colon Cancer
In a pooled analysis of data from clinical trials in the ACCENT/IDEA databases reported in the Journal of Clinical Oncology, Claire Gallois, MD, and colleagues found that patients aged ≥ 70 years receiving oxaliplatin-based adjuvant chemotherapy for stage III colon cancer had a similar time to...
Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone
As reported in The New England Journal of Medicine by de Boniface et al, the phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer and sentinel node metastases. Study Details In ...
B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab
As reported in the Journal of Clinical Oncology by L. Elizabeth Budde, MD, PhD, and colleagues, extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration outpatient ...
Lung Cancer Screening Eligibility: Effect of Using History vs Pack-Year History of Smoking
In a study reported in the Journal of Clinical Oncology, Potter et al found that use of a smoking history of ≥ 20 years rather than the current 2021 U.S. Preventive Services Task Force (USPSTF) guideline of ≥ 20 pack-years would increase the eligibility of Black individuals for lung cancer...
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...
Effect of Virtually Delivered CBT for Insomnia on Cancer-Related Cognitive Impairment
In a Canadian study reported in the Journal of Clinical Oncology, Sheila N. Garland, PhD, and colleagues found that virtually delivered cognitive behavioral therapy for insomnia (CBT-I) improved perceived cancer-related cognitive impairment (CRCI) vs waiting list controls in cancer survivors. Study ...
Anti-CD19 CAR T-Cell Therapy for Richter Transformation
In a retrospective study reported in the Journal of Clinical Oncology, Kittai et al found that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy showed activity in previously treated patients with Richter transformation. Study Details In the study, 69 patients who received CAR T-cell therapy ...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
American Cancer Society Releases Latest Global Cancer Statistics; Cancer Cases Expected to Rise to 35 Million Worldwide by 2050
The American Cancer Society (ACS) has released Global Cancer Statistics 2022, an update of the organization’s report on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022 and 9.7 million people died from the disease...
Danicopan Approved as Add-On Therapy to Ravulizumab or Eculizumab for Extravascular Hemolysis in Adults With Paroxysmal Nocturnal Hemoglobinuria
On April 1, danicopan (Voydeya) was approved by the U.S. Food and Drug Administration (FDA) as add-on therapy to ravulizumab-cwvz or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a first-in-class, oral, Factor D...
Advanced Pancreatic Cancer: Oncolytic Virus–Based Immunostimulatory Gene Therapy Plus Chemotherapy
In a single-center phase I/II study (LOKON001) reported in The Lancet Oncology, Musher et al found that treatment with an oncolytic virus–based immunostimulatory gene therapy (LOAd703) plus chemotherapy was feasible and safe in patients with unresectable or metastatic pancreatic ductal...
HR-Positive, HER2-Negative Metastatic Breast Cancer: Treatment After Disease Progression on CDK4/6 and Aromatase Inhibitors
In the phase II PACE trial reported in the Journal of Clinical Oncology, Erica L. Mayer, MD, MPH, and colleagues found no improvement in progression-free survival with the addition of palbociclib to fulvestrant—but a numeric improvement with the further addition of avelumab—in patients with hormone ...
Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced...
Model for Predicting Outcomes After Sentinel Lymph Node Biopsy in Melanoma
In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma. Study Details The study involved a development cohort of 4,071 patients aged > 13...
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...
Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine...
Pazopanib in Patients With Metastatic Renal Cell Carcinoma and No Evidence of Disease After Metastasectomy
As reported in the Journal of Clinical Oncology by Leonard J. Appleman, MD, PhD, and colleagues, the phase II ECOG-ACRIN E2810 trial showed no significant improvement in disease-free survival with pazopanib vs placebo in patients with metastatic renal cell carcinoma with no evidence of disease...
GU and GI Symptoms With Postprostatectomy Radiotherapy for Prostate Cancer
As reported in JAMA Oncology by Mark K. Buyyounouski, MD, MS, and colleagues, the phase III NRG-GU003 trial showed noninferiority of hypofractionated postprostatectomy radiotherapy (HYPORT) vs conventionally fractionated postprostatectomy radiotherapy (COPORT) for genitourinary (GU) and...
NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy
In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better outcomes than neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC). Study Details A search of published studies reported...
Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022
In a study reported in a research letter in JAMA Network Open, Henderson et al identified prevalence of lung cancer screening in the United States in 2022 using U.S. Preventive Services Task Force (USPSTF) 2021 and 2013 recommendations for screening eligibility. The USPSTF 2013 guidelines...
Early Breast Cancer: Nurse-Led Follow-up Intervention and Quality of Life After Treatment
In a Danish single-institution phase III trial (MyHealth) reported in the Journal of Clinical Oncology, Saltbæk et al found that nurse-led individualized follow-up was associated with significantly better breast cancer–specific quality of life compared with usual care after completion of primary...
Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...
Endoscopic Screening and Esophageal Cancer Incidence and Mortality
In an analysis of 9-year outcomes of a Chinese trial (ESECC) reported in the Journal of Clinical Oncology, Liu et al found that endoscopic screening for esophageal cancer was associated with numeric benefit vs no screening in terms of the incidence of esophageal cancer and esophageal cancer–related ...
Stopping TKI Treatment in Chronic Myeloid Leukemia
In a report in the Journal of Clinical Oncology, Francois-Xavier Mahon, MD, PhD, and colleagues provided the final analysis of the European Stop Kinase Inhibitors (EURO-SKI) study. The trial evaluated the effect of stopping tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid...
Integrated Screening and Stepped Collaborative Care Intervention: Effect on Health-Related Quality of Life in Patients With Cancer
In a phase III trial reported in The Lancet, Jennifer Steel, PhD, and colleagues found that an integrated screening and stepped collaborative care intervention (CARES) improved health-related quality of life vs standard of care in patients with cancer. Study Details In the study, 459 patients from ...
Expert Point of View: Luis Paz-Ares, MD, PhD
The findings from RATIONALE-315 were discussed at the ESMO (European Society for Medical Oncology) Virtual Plenary by Luis Paz-Ares, MD, PhD, Head of the Medical Oncology Service at the Hospital Universitario 12 de Octubre, Madrid. He noted that inhibitors of PD-1 and its ligand PD-L1, as...
